Orchestra BioMed Holdings (OBIO) EBIT (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly EBIT of -$22.1 million for Q1 2026, down 16.67% year-over-year from -$26.5 million in Q1 2025, and down 426.86% quarter-over-quarter from $6.8 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) EBIT (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported EBIT for 6 consecutive years, with -$22.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 16.67% year-over-year to -$22.1 million; the TTM figure through Mar 2026 stood at -$55.0 million (up 20.11% YoY), while the FY2025 annual figure was -$51.8 million, up 19.43% from the prior year.
- EBIT fell to -$22.1 million in Q1 2026 per OBIO's latest filing, from $6.8 million in the prior quarter.
- Across five years, EBIT topped out at $6.8 million in Q4 2025 and bottomed at -$22.1 million in Q1 2026.
- Historically, EBIT has averaged -$13.1 million across 5 years, with a median of -$14.4 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT sank 10577.39% — and 2025, when it jumped 140.5%.
- Orchestra BioMed Holdings' EBIT stood at -$9.8 million in 2022, then dropped by 26.99% to -$12.5 million in 2023, then tumbled by 33.62% to -$16.7 million in 2024, then surged by 140.5% to $6.8 million in 2025, then slumped by 426.86% to -$22.1 million in 2026.
- Business Quant data shows OBIO's EBIT at -$22.1 million in Q1 2026, $6.8 million in Q4 2025, and -$20.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -22.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.36 Mn |
| Mar 31, 2026 | -22.08 Mn |
| Dec 31, 2025 | 6.75 Mn |
| Sep 30, 2025 | -20.31 Mn |
| Jun 30, 2025 | -19.33 Mn |
| Mar 31, 2025 | -18.92 Mn |
| Dec 31, 2024 | -16.68 Mn |
| Sep 30, 2024 | -16.34 Mn |
| Jun 30, 2024 | -16.86 Mn |
| Mar 31, 2024 | -14.42 Mn |
| Dec 31, 2023 | -12.48 Mn |
| Sep 30, 2023 | -14.52 Mn |
| Jun 30, 2023 | -12.96 Mn |
| Mar 31, 2023 | -11.55 Mn |
| Dec 31, 2022 | -9.83 Mn |
| Sep 30, 2022 | -10.07 Mn |
| Jun 30, 2022 | -7.63 Mn |
| Mar 31, 2022 | -5.13 Mn |
| Dec 31, 2021 | -92,045.00 |
| Sep 30, 2021 | -94,445.00 |